TRANSGENICALLY PRODUCED BIOPHARMACEUTICALS COULD SOAR TO

With the possibility of the world's first transgenic plant-produced biopharmaceutical being approved for use this year, worldwide attention is focusing on the futuristic breakthroughs that could dramatically alter the biopharm manufacturing landscape and drive sales past the $12 billion mark by 2012. This is according to a new study from market research firm Kalorama Information, a division of MarketResearch.com, a leading provider of industry-specific market research reports.
Checkbiotech.com